Share class: WuXi AppTec Co., Ltd.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A0387,076,15000 68.23 %
Stock B12,524,851,0531,986,883,615 ( 78.69 %) 0

Major shareholders: WuXi AppTec Co., Ltd.

NameEquities%Valuation
Qatar Holding LLC
9.868 %
38,198,400 9.868 % 168 M ¥
Schroder Investment Management (Hong Kong) Ltd.
4.343 %
16,810,200 4.343 % 74 M ¥
Fidelity Management & Research Co. LLC
4.150 %
16,062,773 4.150 % 71 M ¥
Qatar Investment Authority (Investment Management)
2.157 %
8,349,600 2.157 % 37 M ¥
BlackRock Fund Advisors
1.864 %
7,214,706 1.864 % 32 M ¥
Bosera Asset Management Co., Ltd.
1.501 %
5,810,340 1.501 % 26 M ¥
GF Fund Management Co., Ltd.
1.328 %
5,139,340 1.328 % 23 M ¥
BlackRock Advisors (UK) Ltd.
1.209 %
4,680,873 1.209 % 21 M ¥
FIAM LLC
0.8323 %
3,221,486 0.8323 % 14 M ¥
Zhong Ou Asset Management Co., Ltd
0.8190 %
3,170,024 0.8190 % 14 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
NameEquities%Valuation
Temasek Holdings Pte Ltd. (Investment Management)
4.492 %
114,982,796 4.492 % 636 M ¥
Shanghai Zhongmin Yinfu Capital Management Co. Ltd.
3.402 %
87,074,568 3.402 % 481 M ¥
Zhong Ou Asset Management Co., Ltd
3.047 %
77,977,223 3.047 % 431 M ¥
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)
2.277 %
58,276,626 2.277 % 322 M ¥
Bank of Communications Schroder Fund Management Co., Ltd.
2.165 %
55,424,950 2.165 % 306 M ¥
ICBC Credit Suisse Asset Management Co., Ltd.
1.906 %
48,781,499 1.906 % 270 M ¥
China Asset Management Co., Ltd.
1.410 %
36,083,745 1.410 % 199 M ¥
Hwabao WP Fund Management Co., Ltd.
1.381 %
35,347,130 1.381 % 195 M ¥
GF Fund Management Co., Ltd.
1.280 %
32,753,513 1.280 % 181 M ¥
29,361,931 1.147 % 162 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional35.67%
Individuals0.25%
Unknown64.08%

Based on 1000 largest holdings

Geographical origin of shareholders

Qatar 12.03%
United States 7.21%
China 6.41%
Hong Kong 6.34%
United Kingdom 1.85%
Singapore 0.56%
Sweden 0.27%
Individuals 0.25%
Netherlands 0.18%
Japan 0.14%
Ireland 0.13%
Germany 0.09%
Norway 0.07%
South Africa 0.07%
Australia 0.06%
France 0.06%
Denmark 0.05%
Luxembourg 0.04%
Finland 0.03%
Switzerland 0.02%
Slovenia 0.01%
Canada 0.01%
Austria 0.01%
Taiwan 0.01%
India 0.01%
Malaysia 0.01%

Based on 1000 largest holdings

Logo WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Employees
38,134
Related indices
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW